Gene expression markers for colorectal cancer prognosis
View Patent ↗A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
1. A method of predicting clinical outcome for a human subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising:
determining normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, in a biological sample comprising cancer cells obtained from said human subject, and;
predicting the likelihood of a positive clinical outcome for said human subject based on said normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, wherein said normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, are positively correlated with an increased likelihood of a positive clinical outcome.
2. The method of claim 1 , further comprising determining a normalized expression level of an RNA transcript, or an expression product thereof, of one or more of BGN, MYBL2, FAP, INHBA, and GADD45B in the biological sample;
wherein said normalized expression level of each of BGN, FAP, INHBA, and GADD45B is negatively correlated with an increased likelihood of a positive clinical outcome; and
wherein said normalized expression level of MYBL2 is positively correlated with an increased likelihood of a positive clinical outcome.
3. The method of claim 1 , wherein said normalized expression levels of RNA transcripts of CMYC and Ki-67 are determined using a PCR-based method.
4. The method of claim 1 , wherein said normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, are normalized relative to the expression level of an RNA transcript, or an expression product thereof, of at least one reference gene.
5. The method of claim 1 , wherein said clinical outcome is expressed in terms of Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI).
6. The method of claim 1 , wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colorectal cancer.
7. The method of claim 1 , wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colon cancer.
8. The method of claim 1 , further comprising the step of creating a report summarizing said prediction.
9. A method of predicting in a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer a likelihood of recurrence of colorectal cancer following surgical resection of said cancer, comprising:
determining the normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, in a biological sample comprising cancer cells obtained from said human subject, and;
predicting the likelihood of recurrence of colorectal cancer for the human subject based on the normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, wherein said normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, are negatively correlated with an increased likelihood of recurrence of colorectal cancer.
10. The method of claim 9 , further comprising determining a normalized expression level of an RNA transcript, or an expression product thereof, of one or more of BGN, MYBL2, FAP, INHBA, and GADD45B in the biological sample;
wherein said normalized expression level of each of BGN, FAP, INHBA, and GADD45B is positively correlated with an increased likelihood of recurrence of colorectal cancer; and
wherein said normalized expression level of MYBL2 is negatively correlated with an increased likelihood of recurrence of colorectal cancer.
11. The method of claim 9 , wherein said normalized expression levels of RNA transcripts of CMYC and Ki-67 are determined using a PCR-based method.
12. The method of claim 9 , wherein if said likelihood of recurrence of colorectal cancer is increased, said human subject is subjected to further therapy following said surgical resection.
13. The method of claim 12 , wherein said further therapy is chemotherapy and/or radiation therapy.
14. The method of claim 9 , further comprising the step of creating a report summarizing said prediction.
15. The method of claim 9 , wherein said normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, are normalized relative to the expression level of an RNA transcript, or an expression product thereof, of at least one reference gene.
16. The method of claim 9 , wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colon cancer.